Monitoring of the Ischemic Stroke Patient Through the Use of New Serum Biomarkers and MRI Imaging
NCT ID: NCT05812846
Last Updated: 2023-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
135 participants
OBSERVATIONAL
2018-12-04
2023-06-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers to Predict Hemorrhage and Outcomes After Endovascular Treatment in Patients With Acute Large Vessel Occlusion
NCT03915834
Blod Biomarkers for Stroke
NCT03941249
Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)
NCT02014896
Stroke Imaging Package Study
NCT02485275
Reperfusion Injury After Stroke Study
NCT03041753
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* subjectivity of the patient's clinical evaluation and instrumental data's interpretation
* poor prognostic value of clinical scales;
* poor prognostic value of instrumental measurements;
* difficulty in standardizing and automating clinical/instrumental assessments;
* difficulty in evaluating medical services on a large scale due to the lack of discrete values of treatment efficacy.
The identification and validation of reliable and accessible biomarkers associated with patients' functional recovery could improve their care but still remains a clinical challenge.
Aim of this study will be to measure the levels of circulating biomarkers of brain damage and regeneration in patients affected by ischemic stroke, and to evaluate their prognostic relevance over a 6-month follow-up. Biomarkers' levels will be measured by ELISA and quantitative RT-PCR from the acute event (within 24h from symptoms onset) and in subsequent 4 time-points (7 days, 30 days, 90 days, 180 days post-stroke). Obtained data will be correlated with clinical scales used for patient evaluation and will be associated with MRI-DTI measurements performed in the post-acute (30 days) and post-discharge (180 days) phase.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient able to sign an informed consent, alternatively legal representative or relative
Exclusion Criteria
* Previous head trauma of any entity
* New onset of acute events during the study
* Previous illness, diagnosis or suspicion of current illness with central nervous system involvement
* Diagnosis of cognitive impairment prior to the acute event (MMSE \< 24)
* Need for walking assistance prior to the acute event
* Diagnosis of autoimmune diseases
* Diagnosis of haematological or oncological disease
* Diagnosis of a psychiatric condition: bipolar disorder, psychosis, schizophrenia or suicidal ideation
* Subjects with relative and absolute contraindications to magnetic resonance imaging.
* Life expectancy less than 1 year
* Dependence or abuse of alcohol, drugs or psychotropics prior to the acute event
* Pregnancy in progress
* Severe renal or hepatic insufficiency (Renal disease \> II stage, Child-Plugh score \>5)
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istituti Clinici Scientifici Maugeri SpA
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istituti Clinici Scientifici Maugeri SpA
Pavia, Lombardy, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2250
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.